1)Wong TY, Ferreira A, Hughes R et al:Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization:an evidence-based systematic review. Am J Ophthalmol 157:9-25, 2014
2)Leveziel N, Caillaux V, Bastuji-Garin S et al:Angiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization. Am J Ophthalmol 155:913-919, 2013
3)水川憲一・後藤克聡・岡本宏美・他:近視性脈絡膜新生血管における蛍光眼底造影所見と光干渉断層計所見の比較.臨眼65:295-299,2011
4)Iacono P, Parodi MB, Papayannis A et al:Fluorescein angiography and spectral-domain optical coherence tomography for monitoring anti-VEGF therapy in myopic choroidal neovascularization. Ophthalmic Res 52:25-31, 2014
5)Introini U, Casalino G, Querques G et al:Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization. Eye 26:976-982, 2012
6)Milani P, Pece A, Pierro L et al:Imaging of naive myopic choroidal neovascularization by spectral-domain optical coherence tomography. Ophthalmologica 232:28-36, 2014
7)Bruyere E, Caillaux V, Cohen SY et al:Spectral-domain optical coherence tomography of subretinal hyperreflective exudation in myopic choroidal neovascularization. Am J Ophthalmol 160:749-758, 2015
8)Parodi MB, Iacono P, Bandello F et al:Correspondence of leakage on fluorescein angiography and optical coherence tomography parameters in diagnosis and monitoring of myopic choroidal neovascularization treated with bevacizumab. Retina 36:104-109, 2016
9)藤田和也・武田祥子・中村友子・他:近視性脈絡膜新生血管に対するbevacizumab硝子体内投与1年後の治療成績.眼臨紀4:657-661,2011